Figure 2.

Therapeutic schedules and stopping rules of telaprevir (A) and boceprevir (B) based therapies according to EMA recommendations.

Petta and Craxì BMC Infectious Diseases 2012 12(Suppl 2):S3   doi:10.1186/1471-2334-12-S2-S3